The authoritative source of FDA-approved information on prescription drugs. Physicians have turned to PDR for the latest word on prescription drugs for over 60 years! Today, PDR is considered the standard prescription drug reference and can be found in virtually every physician's office, hospital, and pharmacy in the United States. In fact, nine out of 10 doctors consider PDR their most important drug information reference source. The 61st edition contains more than 3,000 pages-our most comprehensive edition ever! Our new format allows dramatically improved readability and easier access to the information you need now. Among the new drugs featured in this edition are: Amitiza (lubiprostone), a new locally acting chloride-channel activator for the oral treatment of chronic idiopathic constipation in adults Daytrana (methylphenidate transdermal system), a new once-daily transdermal patch formulation of methylphenidate for the treatment of attention deficit hyperactivity disorder Nexavar (sorafenib), a new multi-kinase inhibitor for the treatment of patients with advanced renal cell carcinoma Proquad a new live vaccine for simultaneous vaccination against measles, mumps, rubella (German measles) and varicella (chickenpox) in children 12 months to 12 years of age (Proquad is also approved for use in children 12 months to 12 years of age if a second dose of measles, mumps, and rubella vaccine is to be administered) Ranexa (ranolazine extended-release tablets), a new